



17
KJ
8/16/02
Patent Docket P1467R2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of
Mark Sliwkowski (as amended)
Serial No.: 09/602,812
Filed: June 23, 2000
For: Humanized Anti-ErbB2 Antibodies and
Treatment with Anti-ErbB2 Antibodies

Group Art Unit: 1642

Examiner: J. Hunt


AUG 07 2002
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated below and is addressed to: U.S. Patent and Trademark Office, Washington, D.C. 20231-9999

Express Mail Label No. EV073722836US

August 1, 2002


Wendy M. Lee

REQUEST TO CORRECT INVENTORSHIP UNDER 37 C.F.R. §1.48(b)

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

This Request to correct inventorship is being made pursuant to 37 CFR §1.48(b).

Deletion of the following originally named inventors: Camellia W. Adams and Leonard G. Presta is hereby requested. The above named inventors' invention is no longer being claimed in the application as amended.


The correct inventor of the amended application is: Mark Sliwkowski.

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$130.00 to cover the processing fees for this request as set forth in 37 CFR 1.17(i), and to charge the deposit account for any further fees in regard to this patent application. A duplicate copy of this Request is enclosed for this purpose.

Respectfully submitted,

GENENTECH, INC.

By:


Wendy Lee
Reg. No. 40,378
Telephone No. (650) 225-1994



09157

PATENT TRADEMARK OFFICE

08/06/2002 NM0HAMM1 00000011 070630 09602812

02 FC:122

130.00 CH

ATCC



RECEIVED

AUG 07 2002

TECH CENTER 1600/2900

10801 University Blvd • Manassas, VA 20110-2209 • Telephone: 703-365-2700 • FAX: 703-

BUDAPEST TREATY ON THE INTERNATIONAL RECOGNITION OF
THE DEPOSIT OF MICROORGANISMS FOR THE PURPOSES OF ~~RECEIVED~~

INTERNATIONAL FORM

APR 23 1999

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT ISSUED PURSUANT TO BUDAPEST TREATY 7.3
AND VIABILITY STATEMENT ISSUED PURSUANT TO RULE 40 DEPT.

To: (Name and Address of Depositor or Attorney)

Genentech, Inc.
Attn: Wendy M. Lee
1 DNA Way
South San Francisco, CA 94080-4990

Deposited on Behalf of: Genentech, Inc. (Ref. P712P4C3 and P1467)

Identification Reference by Depositor: ATCC Designation

Murine/Murine Hybridoma cell line 2C4 HB-12697

The deposit was accompanied by: a scientific description a proposed taxonomic description indicated above.

The deposit was received April 8, 1999 by this International Depository Authority and has been accepted.

AT YOUR REQUEST: We will not inform you of requests for the strain.

The strain will be made available if a patent office signatory to the Budapest Treaty certifies one's right to receive, or if a U.S. Patent is issued citing the strain, and ATCC is instructed by the United States Patent & Trademark Office or the depositor to release said strain.


If the culture should die or be destroyed during the effective term of the deposit, it shall be your responsibility to replace it with living culture of the same.

The strain will be maintained for a period of at least 30 years from date of deposit, or five years after the most recent request for a sample, whichever is longer. The United States and many other countries are signatory to the Budapest Treaty.

The viability of the culture cited above was tested April 19, 1999. On that date, the culture was viable.

International Depository Authority: American Type Culture Collection, Manassas, VA 20110-2209 USA.

Signature of person having authority to represent ATCC:


Barbara M. Hailey, Administrator, Patent Depository

Date: April 19, 1999